Bruns Ingmar 4

What Happened Ingmar Bruns, Chief Medical Officer of Zentalis Pharmaceuticals (ZNTL), sold a total of 3,297 shares in two open-market transactions: 2,962 shares on 2026-02-06 at $2.43 each ($7,197) and 335 shares on 2026-02-09 at $2.39 each ($802). The combined proceeds were about $7,999. These were sales (routine cash proceeds), not purchases.

Key Details

• Transactions/dates/prices: 2,962 shares on 2026-02-06 @ $2.43 ($7,197); 335 shares on 2026-02-09 @ $2.39 ($802).
• Total sold: 3,297 shares for ~$7,999.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: F1 — the sales were made automatically by the issuer to cover tax withholding obligations associated with the vesting and settlement of previously granted restricted stock units (RSUs).
• Filing timeliness: Report filed 2026-02-10; appears timely (within the SEC’s two-business-day Form 4 reporting window for the 2026-02-06 and 2026-02-09 transactions).

Context These sales were automatic tax-withholding transactions tied to RSU vesting (i.e., shares were sold to satisfy taxes), which is a common administrative event and not necessarily an expression of the insider’s view on the company. Retail investors typically view routine withholding sales differently than voluntary, open-market sells by insiders.